OmniAb (NASDAQ:OABI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

OmniAb (NASDAQ:OABI) posted its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01, Zacks reports. OmniAb had a negative return on equity of 22.79% and a negative net margin of 275.83%. OmniAb updated its FY 2025 guidance to EPS.

OmniAb Stock Performance

OABI remained flat at $1.48 during mid-day trading on Tuesday. The company had a trading volume of 366,304 shares, compared to its average volume of 536,477. The firm’s fifty day moving average price is $1.61 and its two-hundred day moving average price is $1.70. OmniAb has a 1 year low of $1.22 and a 1 year high of $4.87. The company has a market cap of $213.06 million, a P/E ratio of -2.47 and a beta of 0.15.

Institutional Investors Weigh In On OmniAb

A number of hedge funds have recently bought and sold shares of OABI. AQR Capital Management LLC acquired a new stake in shares of OmniAb during the 1st quarter worth about $25,000. Osaic Holdings Inc. increased its holdings in shares of OmniAb by 214.4% in the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after purchasing an additional 9,716 shares during the period. Cerity Partners LLC boosted its stake in shares of OmniAb by 111.5% in the second quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock valued at $39,000 after buying an additional 11,919 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in shares of OmniAb during the 2nd quarter valued at approximately $53,000. Finally, The Manufacturers Life Insurance Company boosted its position in OmniAb by 20.5% during the second quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company’s stock worth $78,000 after purchasing an additional 7,624 shares in the last quarter. Institutional investors and hedge funds own 72.08% of the company’s stock.

Analyst Ratings Changes

OABI has been the subject of several analyst reports. Royal Bank Of Canada dropped their target price on OmniAb from $4.00 to $3.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Weiss Ratings restated a “sell (e+)” rating on shares of OmniAb in a report on Tuesday, October 14th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.67.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.